Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 140

Sort by

Sort Order Select

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

NOX2 Derived Superoxide Induces Pro-Tumoral p16INK4a Driven Senescence in the AML Bone Marrow Microenvironment

Charlotte Hellmich, MBBChir, BSc, MRCP, Amina Abdul-Aziz, MSc, Yu Sun, BSc, MSc, Christopher Richard Marlein, BSc, Eoghan Forde, Rachel E Piddock, BSc, Manar Shafat, MSc, Adam Morfakis, BSc, Mehta Tarang, Federica Di Palma, Christopher Ingham, Angela Collins, MBBS, Anna Haestier, Bsc, PgD MBBS, MRCOG, Judith Campisi, PhD, Kristian Bowles, MBBS, PhD, Stuart Rushworth, PhD BSc

Blood (2018) 132 (Supplement 1): 2770.

https://doi.org/10.1182/blood-2018-99-115274

Published: 2018

Journal Articles

Evaluation of Oncolytic Viral Therapy Combined with or without Artificial Immunoadjuvant Cell Therapy in Immunocompetent Mouse Tumor Models

Weng-Chit Ung, MSc, Muneyoshi Futami, MD PhD, Kota Sato, MDPhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 5793.

https://doi.org/10.1182/blood-2018-99-112789

Published: 2018

Journal Articles

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Noriyoshi Kurihara, DDS, PhD, Yasuhisa Ohata, MD PhD, Gabriel M. Pagnotti, PhD, John Chirgwin, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4360.

https://doi.org/10.1182/blood.V130.Suppl_1.4360.4360

Published: 2017

Journal Articles

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Blood (2017) 130 (Supplement 1): 3021.

https://doi.org/10.1182/blood.V130.Suppl_1.3021.3021

Published: 2017

Journal Articles

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Eugen Tausch, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Stefan Ibach, Dr, Jenny Saub, Daniel Mertens, PhD, Lars Bullinger, MD, Kirsten Fischer, MD, Valentin Goede, MD, John G. Gribben, MDDSc FMedSci, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 2992.

https://doi.org/10.1182/blood.V130.Suppl_1.2992.2992

Published: 2017

Journal Articles

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

Annika Scheffold, Billy Michael Chelliah Jebaraj, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Daniel Mertens, PhD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 390.

https://doi.org/10.1182/blood.V130.Suppl_1.390.390

Published: 2017

Journal Articles

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Sven Estenfelder, MD, Ann-Kathrin Holland-Letz, Eugen Tausch, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1738.

https://doi.org/10.1182/blood.V130.Suppl_1.1738.1738

Published: 2017

Journal Articles

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Billy Michael Chelliah Jebaraj, PhD, Annika Scheffold, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Valentin Goede, MD, Eugen Tausch, MD, Sven Estenfelder, MD, Veronika Opatrna, MD, Matthias Ritgen, Jacques JM van Dongen, Anton W Langerak, Günter Fingerle-Rowson, MD PhD, Michael Kneba, MD, Kirsten Fischer, MD, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 1708.

https://doi.org/10.1182/blood.V130.Suppl_1.1708.1708

Published: 2017

Journal Articles

Acute Myeloid Leukaemia Induces p16 Driven Senescence in the Bone Marrow Microenvironment to Support Their Proliferation and Survival

Amina Abdul-Aziz, MSc, Manar Shafat, MSc, Rachel Piddock, BSc, Christopher Marlein, BSc, Judith Campisi, PhD, Kristian Bowles, MBBS, PhD, Stuart Rushworth, PhD BSc

Blood (2017) 130 (Supplement 1): 1394.

https://doi.org/10.1182/blood.V130.Suppl_1.1394.1394

Published: 2017

Journal Articles

Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group

Sven Estenfelder, Eugen Tausch, Sandra Robrecht, Jasmin Bahlo, Valentin Goede, Matthias Ritgen, Jacques JM van Dongen, Anton W. Langerak, Günter Fingerle-Rowson, Michael Kneba, Kirsten Fischer, Michael Hallek, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 3227.

https://doi.org/10.1182/blood.V128.22.3227.3227

Published: 2016

Journal Articles

Anti-CD19 Chimeric Antigen Receptor in Hematopoietic Stem Cells Controlled By the Suicide Gene HSV-sr39TK for Immunotherapy of B-Lineage Malignancies

Laurel Christine Truscott, MD, Tzu Ting Chiou, PhD, Satiro N. De Oliveira, MD

Blood (2016) 128 (22): 2317.

https://doi.org/10.1182/blood.V128.22.2317.2317

Published: 2016

Journal Articles

CLL in India May Have a Different Biology from That in the West

Renu Saxena, MD, Ravi Kumar, PhD, Sudha Sazawal, PhD, Manoranjan Mahapatra, MD

Blood (2016) 128 (22): 5574.

https://doi.org/10.1182/blood.V128.22.5574.5574

Published: 2016

Journal Articles

Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT

Mohamad Mohty, MD PhD, Myriam Labopin, MD, Andrea Velardi, MD, Maria Teresa van Lint, MD, Donald Bunjes, Benedetto Bruno, MD PhD, Stella Santarone, MD, Johanna Tischer, Yener Koc, MD, Depei Wu, MDPhD, Zafer Gulbas, MD, Annalisa Ruggeri, MD, Florent Malard, MD PhD, Simona Piemontese, MD, Maria Teresa Lupo Stanghellini, MD, Chiara Bonini, MD, Claudio Bordignon, MD, Fabio Ciceri, MD, Arnon Nagler

Blood (2016) 128 (22): 672.

https://doi.org/10.1182/blood.V128.22.672.672

Published: 2016

Journal Articles

Gene Modification of Human Hematopoietic Stem Cells with Suicide Genes As a Safety Control

Laurel Christine Truscott, MD, Tzu Ting Chiou, PhD, Roy L. Kao, MD, Satiro N. De Oliveira, MD

Blood (2016) 128 (22): 5888.

https://doi.org/10.1182/blood.V128.22.5888.5888

Published: 2016

Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Blood (2016) 128 (22): 4382.

https://doi.org/10.1182/blood.V128.22.4382.4382

Published: 2016

Journal Articles

Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Blood (2016) 128 (22): 4599.

https://doi.org/10.1182/blood.V128.22.4599.4599

Published: 2016

Journal Articles

Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)

Othman Al-Sawaf, MD, Sandra Robrecht, Jasmin Bahlo, Anna Maria Fink, MD, Paula Cramer, MD, Christian Maurer, MD, Manuela A. Bergmann, MD, Martin H. Dreyling, MD PhD, Elisabeth Lange, MD, Michael Kneba, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Michael G Kiehl, MD, Ulrich Jäger, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst, MD, Georg Hopfinger, MD

Blood (2016) 128 (22): 4394.

https://doi.org/10.1182/blood.V128.22.4394.4394

Published: 2016

Journal Articles

Efficient Site-Specific Multi-Gene Engineering of Renewable Pluripotent Cells for Generation of Off-the-Shelf Hematopoietic Immunotherapeutics

Ramzey Abujarour, PhD, Weijie Lan, PhD, Tom Tong Lee, PhD, Greg Bonello, Miguel Meza, MS, Megan Robinson, BS, Raedun Clarke, PhD, Christopher Truong, Chris Lynn, BS, David Robbins, BS, Betsy Rezner, BS, Stewart E. Abbot, PhD BSc, MSc, Daniel Shoemaker, PhD, Bahram Valamehr, PhD MBA

Blood (2016) 128 (22): 5887.

https://doi.org/10.1182/blood.V128.22.5887.5887

Published: 2016

Journal Articles

Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors

Sara Martinelli, MD, Maurizio Cavallari, MD, Luca Formigaro, MD, Enrico Lista, MD, Olga Sofritti, MD, Giulia Daghia, MD, Maria Ciccone, MD, Francesco Cavazzini, MD, Gian Matteo Rigolin, Antonio Cuneo

Blood (2015) 126 (23): 5272.

https://doi.org/10.1182/blood.V126.23.5272.5272

Published: 2015

NARROW

NOX2 Derived Superoxide Induces Pro-Tumoral p16INK4a Driven Senescence in the AML Bone Marrow Microenvironment

Evaluation of Oncolytic Viral Therapy Combined with or without Artificial Immunoadjuvant Cell Therapy in Immunocompetent Mouse Tumor Models

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment

RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group

Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Acute Myeloid Leukaemia Induces p16 Driven Senescence in the Bone Marrow Microenvironment to Support Their Proliferation and Survival

Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group

Anti-CD19 Chimeric Antigen Receptor in Hematopoietic Stem Cells Controlled By the Suicide Gene HSV-sr39TK for Immunotherapy of B-Lineage Malignancies

CLL in India May Have a Different Biology from That in the West

Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT

Gene Modification of Human Hematopoietic Stem Cells with Suicide Genes As a Safety Control

Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)

Efficient Site-Specific Multi-Gene Engineering of Renewable Pluripotent Cells for Generation of Off-the-Shelf Hematopoietic Immunotherapeutics

Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only